The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium

European Journal of Pharmacology

Volumn 512, Issue 2-3, 2005, Pages 207-213

  Juan Fita, María Jesús ^a   Vargas, María Luisa ^a   Hernández, Jesús ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

cAMP; Cardiac contractility; Cilostamide; Dobutamide; Glucagon; Phosphodiesterase inhibitor; Rat ventricle

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; 8 METHOXYMETHYL 3 ISOBUTYL 1 METHYLXANTHINE; 9 (2 HYDROXY 3 NONYL)ADENINE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAMIDE; DOBUTAMINE; GLUCAGON; PHOSPHODIESTERASE 1 INHIBITOR; PHOSPHODIESTERASE 2 INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HEART RIGHT VENTRICLE; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE WALL; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 17444419736     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.01.056     Document Type: Article

References (21)

1. J.A. Beavo Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms Physiol. Rev. 75 1995 725 748
2. D.C. Bode, J.R. Kanter, and L.L. Brunton Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue Circ. Res. 68 1991 1070 1079
3. M. Conti, and S.L. Jin The molecular biology of cyclic nucleotide phosphodiesterases Adv. Nucleic Acid Res. 63 1999 1 38
4. C.L. Emerman Treatment of the acute descompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department Rev. Cardiovasc. Med. 4 2004 S13 S20
5. G.A. Ewy, and J.R. Plachetka Dopamine and dobutamine: pharmacology and use in advanced heart failure G.A. Ewy R. Bressler Cardiovascular Drugs and the Management of Heart Disease 1992 Raven Press New York 65 82
6. M.D. Houslay, and G. Milligan Tailoring cAMP-signalling responses through isoform multiplicity Trends Biochem. Sci. 22 1997 217 224
7. M.J. Juan-Fita, M.L. Vargas, and J. Hernández Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium Pharmacol. Toxicol. 93 2003 23 28
8. M.J. Juan-Fita, M.L. Vargas, A.J. Kaumann, and J. Hernández Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium Naunyn-Schmiedeberg's Arch. Pharmacol. 370 2004 324 329
9. Y. Katano, and M. Endoh Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone and isobutylmethylxantine J. Cardiovasc. Pharmacol. 20 1992 715 722
10. Y. Kitagawa, S. Adachi-Akahane, and T. Nagao Determination of β-adrenoceptor subtype in ventricular myocytes by use of highly selective β-antagonists Br. J. Pharmacol. 116 1995 1635 1643
11. K.M. MacLeod, R.L. Rodgers, and J.H. McNeill Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levels in isolated cardiac preparation on the rat and guinea pig J. Pharmacol. Exp. Ther. 217 1981 798 804
12. J.H. McNeill The effect of dobutamine on rat cardiac cyclic AMP, phosphorilase and force of contraction Res. Commun. Chem. Pathol. Pharmacol. 20 1978 597 600
13. +2 current by activation of adenylyl cyclase and inhibition of phosphodiesterase Nature 345 1990 158 161
14. M. Mongillo, T. McSorley, S. Evellin, A. Sood, V. Lissandron, A. Terrin, E. Huston, H. Hannawacker, M.J. Lohse, T. Pozzan, and M.D. Housley Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartimentalized phosphodiesterases Circ. Res. 95 2004 67 75
15. C.D. Nicholson, R.A.J. Challiss, and M. Shahid Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes Trends Pharmacol. Sci. 12 1991 19 27
16. M. Rivet-Bastide, G. Vandecasteele, S. Hatem, I. Verde, A. Bénardeau, J.J. Mercadier, and R. Fischmeister cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes J. Clin. Invest. 99 1997 2710 2718
17. F.D. Romano, S.G. MacDonald, and J.G. Dobson Adenosine receptor coupling to adenylate cyclase of rat ventricular myocyte membranes Am. J. Physiol. 257 1989 H1088 H1095
18. H.J. Schaeffer, and C.F. Schwender Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines J. Med. Chem. 17 1974 6 8
19. M. Schliwa, R.M. Ezzell, and U. Euteneuer Erythro-9-(3-2(hydroxynonyl)) adenine is an effective inhibitor of cell motility and actin assembly Proc. Natl. Acad. Sci. U. S. A. 81 1984 6044 6048
20. 2+ current in rat ventricular myocytes Br. J. Pharmacol. 127 1999 65 74
21. C.M. White A review of potential cardiovascular uses of intravenous glucagon administration J. Clin. Pharmacol. 39 1999 442 447